Add BrightSurf on Google Email

Folate receptor beta found in pediatric tumors may improve fluorescence-guided cancer surgery

Researchers discovered that folate receptor beta is widely expressed in various pediatric and adolescent solid tumors, making it a promising target for improving tumor surgery accuracy. Pafolacianine, a next-generation dye targeting folate receptors, shows promise as a tumor-agnostic imaging strategy for pediatric cancer surgery.

SourceImpact Journals LLC·JournalOncotarget·TypeNews article·DateOct 20, 2025

Pathogenic germline variants in cancer susceptibility genes

Researchers identified 5.05% of individuals carrying pathogenic variants in key cancer susceptibility genes, highlighting a significant association between these genetic variations and increased cancer risk. The study suggests that more extensive genetic screening for these genes may be warranted to identify high-risk individuals.

SourceJAMA Network·JournalJAMA·DateOct 16, 2025

New JNCCN study confirms it’s ‘never too late’ to see survival benefits from quitting smoking—even with late-stage cancer

Researchers found that patients with stage III or IV cancer who quit smoking lived significantly longer than those who continued smoking, with a two-fold lower rate of all-cause mortality. The study's findings emphasize the crucial role of smoking cessation support as part of standard cancer care.

SourceNational Comprehensive Cancer Network·JournalJournal of the National Comprehensive Cancer Network·DateOct 9, 2025

Smoking and biological sex shape healthy bladder tissue evolution, offering clues to cancer risk

Researchers found that smoking and biological sex shape how normal cells evolve in healthy bladder tissue, with certain mutations gaining an advantage to expand into clones. This study offers new insights into cancer risk and prevention by providing a way to understand tissue evolution and identify early warning signs.

SourceInstitute for Research in Biomedicine (IRB Barcelona)·JournalNature·TypeComputational simulation/modeling·DateOct 8, 2025

Association for Molecular Pathology develops standardized biomarker report template for providers

The Association for Molecular Pathology has created a standardized biomarker report template to simplify complex molecular profiling data presentation to oncologists and healthcare providers. The template includes guidelines for clear formatting, therapeutic guidance, and references to clinical practice guidelines.

SourceAssociation for Molecular Pathology·JournalJournal of Molecular Diagnostics·DateOct 8, 2025

Can digital health tools help younger cancer survivors better predict future health risks?

A groundbreaking study enrolls 465 AYA cancer patients to test if chatbot technology and digital education tools increase uptake of genetic counseling and improve patient outcomes. The trial aims to address longstanding gaps in genetic services for AYAs aged 18-39, who often receive care with limited access to genetic specialists.

SourceAlliance for Clinical Trials in Oncology·TypeRandomized controlled/clinical trial·DateSep 30, 2025

AI model for imaging-based extranodal extension detection and outcome prediction in HPV−positive oropharyngeal cancer

An AI model successfully automates lymph node segmentation and extranodal extension classification from pretreatment CT scans in HPV-associated oropharyngeal carcinoma. Predicted extranodal extension is independently associated with worse oncologic outcomes, highlighting the potential for improved treatment planning.

SourceJAMA Network·JournalJAMA Otolaryngology–Head & Neck Surgery·DateSep 30, 2025

Uncovering EUDAL – An RNA that shields oral cancer from drug therapy

A new study discovers a previously unknown long noncoding RNA, EUDAL, that helps oral cancer cells survive chemotherapy by permanently activating the epidermal growth factor receptor. This RNA molecule blocks the cellular tagging system, allowing EGFR to remain active and promote autophagy in cancer cells.

SourceEditorial Office of West China School of Stomatology, Sichuan University·JournalInternational Journal of Oral Science·TypeExperimental study·DateSep 30, 2025

Ten-year clinical trial report finds radiation comparable to surgery for early-stage non-small cell lung cancer

A new clinical trial report finds that stereotactic radiation therapy offers long-term survival outcomes comparable to surgery for patients with small, early-stage non-small cell lung cancer. The study included a larger patient population than previously published randomized studies and followed these patients for much longer.

First randomized study comparing proton and photon radiation therapy for breast cancer finds both preserve quality of life

A phase III trial comparing proton and photon radiation therapy for breast cancer found that patients report equally strong health-related quality of life with either treatment. Patients treated with protons were more likely to say they would recommend or choose it again, but overall patient-reported outcomes were similar.

Intensity-modulated radiation therapy (IMRT) matches proton therapy in patient-reported outcomes for oropharyngeal cancer

A phase III trial finds that intensity-modulated radiation therapy (IMRT) and proton beam therapy resulted in similar quality-of-life outcomes and low rates of side effects for people with locally advanced oropharyngeal cancer. Excellent tumor control and fewer long-term side effects were seen with both treatments.

Study finds most cancer patients exposed to misinformation. Researchers pilot 'information prescription.'

A study by University of Florida researchers found that 93% of new cancer patients are exposed to at least one type of misinformation about cancer treatments. The most common sources were second-hand information from friends, family, social media, and news outlets. The study suggests that clinicians should assume their patients have be...

SourceUniversity of Florida·JournalJournal of Cancer Education·TypeSurvey·DateSep 24, 2025

Zebrafish models offer fast and effective guidance for personalized therapies for kids with high-risk cancer

New research reveals that zebrafish models can help guide clinical decision-making in real-time for challenging pediatric cancer cases. The study shows that pre-clinical zebrafish models accurately predicted responses to 11 of 12 treatment regimens, providing robust and actionable treatment response data.

SourceChildren's Hospital of Eastern Ontario Research Institute·JournalCancer Research Communications·TypeExperimental study·DateSep 24, 2025

Mammograms may benefit women well into their 80s, UCLA study finds

A new study from the University of California - Los Angeles Health Sciences suggests that regular mammograms may still offer significant benefits for women in their 80s. The study found that screened women were more likely to have surgery to remove the tumor and had a lower risk of cancer returning and dying compared to unscreened women.

SourceUniversity of California - Los Angeles Health Sciences·JournalAnnals of Surgical Oncology·DateSep 22, 2025

Graz University of Technology opens up new avenues in lung cancer research with digital cell twin

Researchers at Graz University of Technology created a highly detailed digital twin of the A549 lung cancer cell line, paving the way for individualized cancer treatment. The model simulates calcium dynamics and electrical voltages, allowing for testing of drugs and personalized treatment strategies.

SourceGraz University of Technology·JournalClinical and Translational Medicine·TypeComputational simulation/modeling·DateSep 18, 2025

New research in JNCCN offers a simplified way to identify harmful medications in older adults with cancer

Researchers evaluated a tool based on NCCN Guidelines to identify high-risk medications and their association with frailty and outcomes in over 380,000 older adults diagnosed with cancer. The study found that each additional high-risk medication increased the odds of being mildly or moderately-to-severely frail by 66%.

SourceNational Comprehensive Cancer Network·JournalJournal of the National Comprehensive Cancer Network·DateSep 10, 2025